Sep 28, 2026 08:40AM
Sep 28, 2026 08:40AM
Sep 8, 2026 08:15AM
Sep 8, 2026 08:15AM
Aug 27, 2026 09:01AM
Aug 27, 2026 09:01AM
Aug 24, 2026 09:05AM GRI Bio to present Phase 2a IPF drug data at ERS Congress in September
Aug 24, 2026 09:05AM
Jun 18, 2026 08:32AM
Jun 18, 2026 08:31AM
May 18, 2026 09:15AM
May 14, 2026 08:35AM
May 14, 2026 08:35AM
Feb 5, 2026 09:15AM GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
Feb 4, 2026 08:47AM
Feb 4, 2026 08:45AM
Jan 28, 2026 08:45AM
Jan 28, 2026 08:45AM
Jan 26, 2026 08:30AM
Jan 21, 2026 04:01PM
Jan 21, 2026 04:01PM GRI Bio Announces Reverse Stock Split
Jan 8, 2026 08:00AM
Jan 8, 2026 08:00AM
Dec 12, 2025 04:05PM
Dec 12, 2025 04:05PM
Dec 11, 2025 09:15AM
Dec 11, 2025 09:15AM
Dec 10, 2025 04:05PM GRI Bio reports positive phase 2a trial results for IPF treatment
Dec 10, 2025 04:05PM
Sep 11, 2025 08:45AM
Sep 11, 2025 08:45AM
Jul 31, 2025 09:00AM
Jul 31, 2025 09:00AM
Jul 1, 2025 08:45AM
Jun 26, 2025 08:08AM GRI Bio's (GRI) GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis
Jun 26, 2025 08:00AM
May 22, 2025 08:03AM
May 22, 2025 08:00AM
May 15, 2025 08:35AM
May 15, 2025 08:35AM
May 8, 2025 08:48AM
May 8, 2025 08:45AM GRI Bio’s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) 
May 7, 2025 09:15AM
Apr 16, 2025 08:35AM
Apr 2, 2025 04:05PM
Apr 1, 2025 11:15AM
Apr 1, 2025 11:15AM
Apr 1, 2025 09:00AM
Apr 1, 2025 09:00AM GRI Bio Reports Encouraging Interim 2-Week Safety Results from Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)
Mar 31, 2025 08:03AM

1,199,788 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All